Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis

SIMPLE SUMMARY: Renal cell carcinoma (RCC) is the most common kidney malignancy. Due to development of therapy resistance, efficacy of conventional drugs such as sunitinib is limited. Artesunate (ART), a drug originating from Traditional Chinese Medicine, has exhibited anti-tumor effects in several...

Descripción completa

Detalles Bibliográficos
Autores principales: Markowitsch, Sascha D., Schupp, Patricia, Lauckner, Julia, Vakhrusheva, Olesya, Slade, Kimberly S., Mager, René, Efferth, Thomas, Haferkamp, Axel, Juengel, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692972/
https://www.ncbi.nlm.nih.gov/pubmed/33121039
http://dx.doi.org/10.3390/cancers12113150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692972/
https://www.ncbi.nlm.nih.gov/pubmed/33121039
http://dx.doi.org/10.3390/cancers12113150

Ejemplares similares